Drug intelligence / Profile preview

REGN6490

Development stage: Discontinued
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

REGN6490 is a monoclonal antibody developed by Regeneron Pharmaceuticals that targets the interleukin 36 receptor (IL-36R). It acts as an antagonist of IL-36R, thereby inhibiting the pro-inflammatory signaling mediated by this receptor. The drug was investigated primarily for the treatment of palmoplantar pustulosis, a chronic inflammatory skin disorder characterized by pustules on the palms and soles. REGN6490 reached phase 1 clinical trials but development was discontinued prior to completion[1][2][5][8].

Targets

IL1RL2 (Interleukin 36 Receptor)

Beyond the preview

Go deeper on REGN6490.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGN6490.

Explore the full profile